The identification of the invasive and clonogenic advantages conferred by HES6 to cancer cells and the discovery of other cellular pathways that HES6 activates may reveal new ways to interfere with prostate cancer progression—discoveries that could ultimately lead to the development of novel therapies for men with aggressive prostate tumours. This evidence concerns the gene HES6 and prostate carcinoma.